Gender‐affirming hormone therapy: Effect on semen quality and use of fertility preservation
Andrology · 2026
DOI: 10.1111/andr.70112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Andrology, 2026. Verfasst von Anna Chiara Conflitti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Seminology - Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Roma, Italy. Hauptthemen laut MEDLINE: Fertility Preservation, Semen Analysis, Gender-Affirming Procedures. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Education and Research, University of Rome "Sapienza", Italy.
Abstract (Originalsprache)
Fertility preservation (FP) is a fundamental part of gender care. Gender‐affirming hormone therapy (GAHT) involves the use of drugs that could be potential risk factors for fertility. Therefore, FP is recommended before beginning the gender‐affirmation process. This narrative review aims to assess several aspects, mainly concerning the assigned male at birth (AMAB) population. The purpose of this review is to provide an overview of the effects of GAHT on testicular morphology and seminal quality, the use of semen cryopreservation, the desire for parenthood among transgender people, the factors influencing the decision to use fertility preservation (FP) and suggestions for improving clinical practice. A literature search within PubMed was conducted and the results deal with issues such as changes in testicular morphology and semen quality, FP utilization, barriers to treatment, current clinical practice models, and suggestions for improving transgender adolescents access to FP. The results showed that GAHT can have a negative effect on fertility in transgender AMAB subjects. It is therefore recommended to carry out FP before starting such treatment. However, there is low percentage of utilization to FP among transgender adolescents. In deciding whether to pursue FP, they consider many factors: future parenting desires, individual experiences of gender dysphoria, family values around biological parenting, financial considerations, and the availability of fertility information. A discrepancy emerged between the rate of desire to become a parent and the actual rate of FP utilization. The reasons are various, such as cost, and concern in delaying the initiation of treatment. Suggestions for improving clinical practice are also provided from this literature search.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Seminology - Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Roma, Italy.
- Department of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.
Förderung
- Italian Ministry of Education and Research
- University of Rome "Sapienza", Italy
Zitieren
APA
Conflitti, A. C., Buonacquisto, A., Cicolani, G., Di Chiano, S., Ruberto, M., Pallotti, F., Lombardo, F., & Paoli, D. (2026). Gender‐affirming hormone therapy: Effect on semen quality and use of fertility preservation. Andrology. https://doi.org/10.1111/andr.70112
Vancouver
Conflitti AC, Buonacquisto A, Cicolani G, Di Chiano S, Ruberto M, Pallotti F, et al. Gender‐affirming hormone therapy: Effect on semen quality and use of fertility preservation. Andrology. 2026. doi:10.1111/andr.70112
BibTeX
@article{Conflitti2026,
author = {Conflitti, Anna Chiara and Buonacquisto, Alessandra and Cicolani, Gaia and Di Chiano, Silvia and Ruberto, Marta and Pallotti, Francesco and Lombardo, Francesco and Paoli, Donatella},
title = {Gender‐affirming hormone therapy: Effect on semen quality and use of fertility preservation},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70112}
}
EUVIMED